Lv1
30 积分 2022-09-22 加入
Eculizumab in refractory myasthenia gravis: a real-world single-center experience
9小时前
待确认
Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study
12小时前
待确认
Efgartigimod: A Review in Generalised Myasthenia Gravis
12小时前
求助中
质子泵抑制剂注射剂型的稳定性和安全性
1天前
已关闭
Batoclimab vs Placebo for Generalized Myasthenia Gravis
7天前
已完结
Analysis of clinical features and outcomes in patients with ocular myasthenia gravis according to anti-acetylcholine receptor antibody-seropositivity
22天前
已完结
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
22天前
已完结
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
22天前
已完结
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors
3个月前
已完结
AChR-seropositive myasthenia gravis in muscular dystrophy: diagnostic pitfalls and clinical management challenges
3个月前
已完结
皖公网安备34019202002308
